WILLS EYE IS HIRING – CLICK HERE TO APPLY TODAY!

Crane
RETINA
Carl D. Regillo, MD

Chief, Retina Service, Wills Eye Hospital
Professor, Ophthalmology
Sidney Kimmel Medical College at Thomas Jefferson University

Research Interests: Designing and conducting collaborative clinical trials of new therapeutics to improve visual outcomes for both common and rare retinal diseases with a focus on sustained delivery including gene therapy and slow-release platforms

1.    Garg SJ, Regillo CD. Management of large submacular hemorrhage secondary to neovascular AMD. Ophthalmology Retina 2025;1:1-2
2.    Khanani AM, Campochiaro PA, Graff JM, Marcus DM, Miller D, Mittra RA, Regillo C, Sheth VS, Bobbala A, Gune S, Lin S, Quezada-Ruiz C, Malhotra V. Continuous ranibizumab via port delivery sysmte vs monthly ranibizumab for treatment of diabetic macular edema: The Pagoda randomized clinical trial. JAMA Ophthalmol 2025 (epub Mar 6)
3.    Regillo CD, Nijm LM, Shechtman DL, Kaiser PK, Karpecki PM, Ryan EH, Ip MS, Yeu E, Kim T, Rafieetary MR, Donnenfeld ED. Considerations for the identification and management of geographic atrophy: Recommendations from an expert panel. Clin Ophthalmol 2024;18:325-335.
4.    Clark AJ, Regillo C, Gune S, Pieramici DJ. Refillable drug reservoirs for retinal diseases. Am J Ophthalmol 2024 (epub Nov 26)
5.    Pandit SA, Momenaei B, Wakabayashi T, Mansour H, Vemula S, Durrani AF, Pashaee B, Kazan AS, Ho AC, Klufas MA, Regillo CD, Yonekawa Y, Hsu J, Kuriyan AE, Chiang A. Clinical outcomes of faricimab in patients with previously-treated neovascular AMD. Ophthalmology Retina 2024;8:360-366.
6.    Wykoff CC, Kupperman BD, Regillo CD, Chang M, Hariprasad, Duker JS, Altaf S, Saim S. Extended intraocular drug-delivery platforms for the treatment of retinal and choroidal diseases. J of Vitreoret Dis. 2024;8:577-586.
7.    Starr MR, Hinkle JC, Patel LG, Ammar MJ, Soares RR, Patel SN, Cohen MN, Hsu J, Yonekawa Y, Ho AC, Regillo CD, Gupta OP. Randomized trial comparing microserrated versus conventional ILM foreceps for ILM peeling. Retina 2024;44:1323-1328.
8.    Kaufmann GT, Gupta O, Yu J, Nguyen M, Lee CY, Achuck K, Hsu J, Ho A, Regillo C, Garg S, Klufas MA, Mehta S, Xu D, Cohen M, Yonekawa Y, Kuriyan A, Starr MR. Vitreoretinal outcomes following secondary intraocular lens implantation with pars plana vitrectomy. Retina 2024;44:1337-1343
9.    Momenaei B, Pandit SA, Wang KY, Wakabayashi T, Hsu J, Regillo CD, Klufas MA, Xu D, Cohen MN, Garg SJ, Kuriyan AE, Yonekawa Y. Suprachoroidal triamcinolone acetonide for refractory postoperative cystoid macular edema. Retina 2024;44:1379-1386
10. Cappellani F, Regillo CD, Haller JA, Gagliano C, Pulido JS. Exploring the associated genetic causes of diabetic retinopathy as a model of inflammation in retinal disease. Int J Mol Sci 2024;25:5456.
11. Sepah YJ, Do DV, Mesquida M, Day BM, Blotner S, Afridi R, Halim MS, Hong K, Wakshull E, Fauser S, Stoilov I, Dong Nguyen Q; HARBOR; READ-3 Investigators. Aqueous humor interleukin-6 and vision outcomes with anti-VEGF therapy. Eye 2024;38:1755-1761
12. Sharma A, Wu L, Bloom S,Stanga P, Abreu N, Eichenbaum D, Regillo C, Guymer R, Harjot Madan K, Rezaei KA. RWC Update: Removal of subretinal band without retinotomy; geographic atrophy: How do you select appropriate patients for anti-complement therapy; shaken baby syndrome. Ophth Surg Lasers Imaging Ret 2024;6:305-308.
13. Wykoff CC, Avery RL, Barakat MR, Boyer DS, Brown DM, Brucker AJ, Cunningham ET, Heier JS, Holekamp NM, Demirci H, Regillo CD, Yiu GC, Ciulla TA. Suprachoroidal space injection techniquw: Expert panel guidance. Retina 2024;44:939-949.
14. Sharma A, Wakabayashi T, Regillo CD, Cheung CMG, Loewenstein A, Zur D, Goldberg D, Hilely A, Ozdek S, Özdemir HB, Parachuri N, Kumar N, Kuppermann BD, Bandello F, Querques G. Subfoveal neurosensory detachment flattening and observe approach for the management of Ci-DMO-a multicentric study. Eye 2024;38:3272-3278 (epub Aug 3)
15. Mahmoudzadeh R, Swaminathan S, Salabati M, Wakabayashi T, Patel D, Mehta S, Kuriyan AE, Khan MA, Klufas MA, Garg SJ, Gupta OP, Regillo CD, Yonekawa Y, Cohen MN. Retinal displacement following retinal detachment repair. Ophth Surg Lasers Imaging Ret 2024 Jul1:1-7
16. Durrani AF, Momenaei B, Wakabayashi T, Vemula S, Pandit SA, Hsu J, Ho AC, Spirn MJ, Klufas MA, Garg SJ, Vander JF, Regillo CD, Chiang A, Kuriyan AE, Yonekawa Y. Conversion to faricimab after prior antivascular endothelial growth factor therapy for persistent diabetic macular edema. Br. J Ophthalmol 2024;108:1257-1262 (epub Feb 12)
17. Israilevich RN, Mansour H, Patel SN, Garg SJ, Klufas MA, Yonekawa Y, Regillo CD, Hsu J. Risk of endophthalmitis based on cumulative number of anti-VEGF intravitreal injections. Ophthalmology 2024;131:667-673 (epub Jan 3)
18. Hasan N, Mehrotra K, Danzig CJ, Eichenbaum DA, Ewald A, Regillo C, Momenaei B, Sheth VS, Lally DR, Chhablani J. Screen failures in clinical trials in retina. Ophthalmol Retina 2024;8:1093-1099 (epub May 27)
19. Wykoff CC, Avery RL, Barakat MR, Boyer DS, Brown DM, Brucker AJ, Cunningham ET Jr, Heier JS, Holekamp NM, Kaiser PK, Khanani AM, Kim JE, Demirci H, Regillo CD, Yiu G, Ciulla TA. Suprachoroidal space injection technique: Expert panel guidance. Retina 2024 (epub Mar 5)
20. Mandava NK, Kuriyan AE, Ho AC, Hsu J, Regillo CD, Klufas MA. Enhanced durability and evolution of retreatment criteria of intravitreal antivascular endothelial growth factor agents for diabetic macular edema. Curr Opin Ophthalmol 2024;35:197-204 (epub Feb 12)
21. Khanani AM, Boyer DS, Wykoff CC, Regillo CD, Busbee BG, Pieramici D, Danzig CJ, Joondeph BC, Major JC Jr, Turpcu A, Kiss S. Safety and efficacy of ixoberogene soroparvovec in neovascular AMD in the United States (OPTIC): a prospective, two-year, multicenter phase 1 study. EClinicalMedicine 2023;67:102394
22. Jackson TL, Slakter J, Buyse M, Wang K, Dugel PU, Wykoff CC, Boyer DS, Gerometta M, Baldwin ME, Price CF; Opthea Study Group Investigators. A randomized control trial of OPT-302, a VEGF-C/D inhibitor for neovascular AMD. Ophthalmology 2023;130:588-597 (epub Feb 6, 2023)
23. Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. TENAYA and LUCERNE: Two-year results form the phase 3 neovascular AMD trials of faricimab with treat-and-extend dosing in year 3. Ophthalmology 2024;131:914-926 (epub Feb 19)
24. Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Faricimab treat-and-extend for diabetic macular edema: Two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology 2024; 131:708-723 (epub Dec 28, 2023)
25. Mahmoudzadeh R, Williamson JE 3rd, Salabati M, Soares RR, Gupta OP, Regillo CD, Ho AC, Hsu J. OCT-based description of spontanteous reattachment of macula-off tractional retinal detachment with significant visual improvement. Journal of Vitreoretinal Dis 2024;8:101-104.
26. Wakabayashi T, Shiraki N, Tsuboi K, Oshima Y, Abe K, Yamamoto Y, Hisashi F, Baba K, Ishida Y, Otsuka Y, Shiraki A, Suzue M, Hashimoto R, Venkatesh R, Chhablani J, Gomi F, Kamei M, Maeno T, Regillo CD, Yonekawa Y, Ikuno Y; SCHISIS Study Group. Risk factors and outcomes of postoperative macular hole formation after vitrectomy for myopic traction maculopathy: SCHISIS Report No. 2. Ophthalmol Retina 2023;9:779-787.
27. Park JG, Adrean SD, Begaj T, Capone A Jr, Charles S, Chen SN, Chou HD, Cohen MN, Corona ST, Faia LJ, Garg SJ, Garretson BR, Gregori NZ, Haller JA, Houghton OM, Hsu J, Jo J, Kaiser RS, Lai CC, Mahgoub MM, Mansoor M, Matoba R, Morizane Y, Nehemy MB, Raphaelian PV, Regillo CD, Ruby AJ, Runner MM, Sneed SR, Sohn EH, Spirn MJ, Vander JF, Wakabayashi T, Wolfe JD, Wykoff CC, Yonekawa Y, Yoon YH, Mahmoud TH. Surgical management of full-thickness macular holes in macular telangiectasia Type 2: A global multicenter study. Ophthalmology 2024;131:66-77 (epub Sep 3, 2023)
28. Wykoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS, Agostini HT, Chang A, Laude A, Wachtlin J, Kovacic L, Wang L, Wang Y, Bouillaud E, Brown DM. Kestrel and Kite phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema. Am J Ophthalmol 2024;260:70-83 (epub Jul 15, 2023)
29. Akhlaq A, Williams D, Clark WL, Khan H, Khanani AM, Walden L, Awh C, Graff JT, Graff JM, Wakabayashi T, Regillo C, Maass KF, Callaway N, Gune S, Campochiaro PA. Exudation in patients with neovascular AMD with port delivery system or monthly injections. Am J Ophthalmol 2024;258:158-172 (epub Jul 13, 2023)
30. Kymes SM, Oden NL, VanVeldhuisen PC, Scott IU, Ip MS, Blodi BA, King J; SCORE2 Investigator Group. Cost-utility comparison of bevacizumab and aflibercept in the treatment of central or hemi-retinal vein occlusion in the SCORE2 trial. JAMA Ophthalmol 2023;141:554-561
31. Wakabayashi T, Patel N, Bough M, Nahar A, Sheng Y, Momenaei B, Salabati M, Mahmoudzadeh R, Kuriyan AE, Spirn MJ, Chiang A, Hsu J, Fineman MS, Regillo CD, Sivalingam A, Ho AC, Gupta OP, Yonekawa Y. Vitrectomy for vitreous hemorrhage associated with retinal vein occlusion: Visual outcomes, prognostic factors and sequelae. Retina 2023;43:1506-1513.
32. Xue K, Hua P, Maguire MG, Daniel E, Jaffe GJ, Grunwald JE, Ying GS; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Prediction of 2-year outcomes using early morphologic and functional responses in CATT trials. Ophthalmol Retina 2023;7:564-572.
33. Kaiser PK, Karpecki PM, Regillo CD, Baumal C, Ryan EH, Ip MS, Modi Y, Yeu E, Nijm L, Farid M, Rebenitsch RL, Kim T, Shechtman DL, Nichols K, Schweitzer J, Dunbar MT, Rafieetary MR, Donnenfeld ED. Geographic atrophy management consensus (GA-MAC): a Delphi panel study on identification, diagnosis and treatment. BMJ Open Ophthalmol 2023 Oct 8.
34. Awh KC, Mahmoudzadeh R, Salabati M, Mansour HA, Bechay J, Magagna J, Regillo CD, Ho AC, Garg SJ, Hsu J. Outcomes of intentially suspending treatment in eyes with advanced neovascular AMD. Am J Ophthalmology 2023;256:20-26.
35. Pandit SA, Momenaei B, Wakabayashi T, Mansour HA, Vemula S, Durrani AF, Pashaee B, Kazan AS, Ho AC, Klufas M, Regillo C, Yonekawa Y, Hsu J, Kuriyan A, Chiang A. Real world outcomes of faricimab in patients with previously treated neovascular AMD. Ophthalmology Retina 2024;8:360-366 (epub Oct 30, 2023)
36. Wakabayashi T, Torjani A, Mahmoudzadeh R, Swaminathan S, Mansour HA, Salabati M, Yonekawa Y, Regillo CD. Risk factors for epiretinal membrane after rhegmatogenous retinal detachment repair: Quantitative ultra widefield imaging analysis. Ophthalmic Surg Lasers Imaging 2023;54:206-216.
37. Weng CY, Singh RP, Gillies MC, Regillo CD. Optimizing visual outcomes in patients with neovascular AMD: the potential value of sustained anti-VEGF therapy. Ophthalmic Surg Lasers Imaging 2023;54:654-659.
38. Jackson TL, Slakter J, Buyse M, Wang K, Dugel PU, Wykoff CC, Boyer DS, Gerometta M, Baldwin ME, Price CF; Opthea Study Group Investigators. A randomized, controlled trial of OPT-302, a VEGFC-D inhibitor for neovascular AMD. Ophthalmology 2023;130:588-597.
39. Bonnar J, Han Tan C, McCullough P, Wright DM, Williamson T, Lois N, IRB-RRD Study Gorup. Scleral buckle, vitrectomy or combined surgery for inferior break retinal detachment: Systematic review and meta-analysis. Ophthalmology Retina 2023;10:837-847 [epub May 13]
40. Regillo C, Berger B, Brooks L, Clark WL, Mittra R, Wykoff CC, Callaway NF, DeGraaf S, Ding HT, Fung AE, Gune S, Le Pogam S, Smith R, Willis JR, Barteselli G. Archway phase 3 trial of the port delivery system with ranibizumab for noevascular AMD: 2 year results. Ophthalmology 2023;130:735-747 [epub Mar 2]
41. Shah SM, Eliott D, Cox JT, Yonekawa Y, Mahmoudzadeh R, Peck TJ, Regillo CD, Ho AC, Oellers P, Choudhury M, Arboleda N, Gentile RC, Sun V, Iezzi R. Epiretinal membrane with foveal herniation: Visual and surgical outcomes. Retina 2023;43:182-190.
42. Sharma A, Holz FG, Regillo CD, Freund KB, Sarraf D, Khanani AM, Baumal C, Holekamp N, Tadayoni R, Kumar N, Parachuri N, Kuppermann BD; International Retina Biosimilar Study Group (Inter BIOS Group); International Retina Biosimilar Study Group (Inter BIOS Group); Bandello F, Querques G, Loewenstein A, Özdek Ş, Rezai K, Laurent K, Bilgic A, Lanzetta P, Zur D, Yannuzzi N, Corradetti G, Kaiser P, Hilely A, Boyer D, Rachitskaya A, Chakravarthy U, Wintergerst M, Sarao V, Parolini B, Mruthyunjaya P, Nguyen QD, DO D, Keane PA, Hassan T, Sridhar J, Eichenbaum D, Grewal D, Splitzer M. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER survey). Expert Opin Bio Ther 2023;23:851-859 [Epub Feb 19]
43. Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two, randomized, double-masked, phase 3, noninferiority trials. Lancet 2022;399:729-740 [epud Jan 24]
44. Lee IJ, Pulido JS, Regillo CD, Leys M. Multiple organ dysnfunction syndrome and disseminated intravascular coagulation causing extensive multiple Amalric triangular choroidal infarctions. Retina Cases Brief Rep 2024;18:251-254 [Epub Nov 8, 2022]
45. Regillo C, Singh R, Hamilton R, Gedif K, Best C, Koh A, Holz FG. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials. Ophthalmologica 2022;245(5):403-412 (Epub 2022 Apr 25)
46. Hutton DW, Glassman AR, Liu D, Sun JK; DRCR Retina Network. Cost-effectiveness of aflibercept vs bevacizumab first followed by aflibercept if needed for diabetic macular edema. JAMA Ophthalmology 2023;141:268-274 [Epub Feb 2]
47. Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C; all Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2022;129:295-307 [epub Sep 21, 2021]
48. Wang R, McClard CK, Laswell S, Mahmoudzadeh R, Salabati M, Ammar M, Vannavong J, Aziz AA, Ewald A, Calvanese A, Lehman EB, Fried S, Windham V, Strutt A, Saroj N, Khanani AM, Eichenbaum DA, Regillo CD, Wykoff CC. Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). BMJ Open Ophth 2022;7:e001188
49. Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to 16 weeks in patients with diabetic macular edema (YOSEMITE and RHINE): two, randomized, double-masked, phase 3 trials. Lancet 2022;399:741-755 [epub Jan 24]
50. Lim JI, Regillo CD, Sadda SR, Ipp E, Bhaskaranand M, Ramachandra C, Solanki K. Artificial Intelligence Detection of Diabetic Retinopathy: Subgroup Comparison of the EyeArt System with Ophthalmologists' Dilated Examinations. Ophthalmol Sci. 2022 Sep 30;3(1):100228. (eCollection 2023 Mar)
51. Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network. Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema. N Engl J Med 2022 Aug 25;387(8):692-703. (Epub 2022 Jul 14)
52. Israilevich RN, Starr MR, Mahmoudzadeh R, Salabati M, Swaminathan V, Huang D, Kuriyan AE, Yonekawa Y, Garg SJ, Mehta S, Regillo CD, Hsu J. Factors Associated With Good Visual Acuity Outcomes After Retinectomy in Eyes With Proliferative Vitreoretinopathy. Am J Ophthalmol. 2022;240:143-148 (Epub 2022 Mar 12)
53. Core JQ, Hua P, Daniel E, Grunwald JE, Jaffe G, Maguire MG, Ying GS; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials. Br J Ophthalmol. 2023;7:1000-1006 Apr 15:bjophthalmol-2021-320665
54. Ali FS, Jenkins TL, Boparai RS, Obeid A, Ryan ME, Wibblesman TD, Chiang A, Garg SJ; Post-Injection Endophthalmitis Study Group. Aqueous chlorhexidine compafed with povidone-iodine as ocular antisepsis before intravitreal injection: A randomized clinical trial. Ophthalmol Retina 2021:5:788-796.
55. Core JQ, Pistilli M, Hua P, Daniel E, Grunwald JE, Toth CA, Jaffe GJ, Martin DF, Maguire MG, Ying GS; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Predominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmol Retina. 2022 Sep;6(9):771-785. (Epub 2022 Apr 9)
56. Gopal A, Starr M, Obeid A, Ryan E, Ryan C, Ammar M, Patel L, Forbes N, Capone A Jr, Emerson G, Joseph D, Eliott D, Regillo C, Hsu J, Gupta O, Kuriyan A, Yonekawa Y. Predictors of Vision Loss after Surgery for Macula-Sparing Rhegmatogenous Retinal Detachment. Curr Eye Res. 2022 Aug;47(8):1209-1217. (Epub 2022 Jun 6)
57. Mahmoudzadeh R, Israilevich R, Salabati M, Hsu J, Garg SJ, Regillo CD, Ho AC, Khan MA. Pars Plana Vitrectomy for Idiopathic Epiretinal Membrane: OCT Biomarkers of Visual Outcomes in 322 Eyes. Ophthalmol Retina. 2022 Apr;6(4):308-317 (Epub 2021 Oct 27)
58. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group. Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18. JAMA Ophthalmol. 2022 May 1;140(5):458-464.
59. Starr MR, Cai L, Obeid A, Ryan EH, Eliott D, Ryan C, Forbes NJ, Ammar M, Patel LG, Capone A, Emerson GG, Joseph DP, Gupta OP, Regillo CD, Hsu J, Yonekawa Y; Primary Retinal Detachment Outcomes (PRO) Study Group. Risk factors for cystoid macular edema following rhegmatogenous retinal detachment. Curr Eye Res 2021;46:1867-1875. [epub May 21]
60. Starr MR, Lee C, Arias D, Mahmoudzadeh R, Salabati M, Kuriyan AE, Regillo CD, Hsu J, Yonekawa Y, Gupta OP. Full-thickness macular holes after surgical repair of primary rhegmatogenous retinal detachment: incidence, clinical characteristics and outcomes. Graefes Arch Clin Exp Ophthalmol 2021;259:3305-3310 [epub Jun 21]
61. Cai LZ, Lin J, Starr MR, Obeid A, Ryan EH, Ryan C, Forbes NJ, Arias D, Ammar MJ, Patel LG, Capone A, Emerson GG, Joseph DP, Eliott D, Gupta OP, Regillo CD, Hsu J, Yonekawa Y; Primary Retinal Detachment Outcomes (PRO) Study Group. Pro score: predictive scoring system for visual outcomes after rhegmatogenous retinal detachment repair. B J Ophthalmol 2023;107:555-559 [epub Nov 23, 2021]
62. Salabati M, Mahmoudzadeh R, Starr MR, Zhang Q, Sharpe J, Hsu J, Ho AC, Regillo C, Kuriyan AE. REFRACTIVE ERROR CHANGE DURING TREATMENT OF DIABETIC MACULAR EDEMA: A Post Hoc Analysis of the Diabetic Retinopathy Clinical Research Protocol T Trial. Retina. 2022 Nov 1;42(11):2059-2065.
63. Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group. Intraocular pressure-related events after anti-vascular endothelial growth factor therapy got macular edema due to central retinal vein occlusion or hemiretinal vein occlusion: SCORE2 Report 16 on a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 2021[epub Oct 28]
64. Salabati M, Mahmoudzadeh R, Wong JC, Patel D, Patel SN, Obeid A, Sivalingam A, Vander JF, Garg SJ, Ho AC, Regillo CD, Hsu J. Outcomes of eyes with retinal vein occlusion that are lost to follow-up after antivascular endothelial growth factor therapy. Br J Ophthalmol 2022;106:1742-1747 [epub Jun 28]
65. Ipp E, Liljenquist D, Bode B, Shah VN, Silverstein S, Regillo CD, Lim JI, Sadda S, Domalpally A, Gray G, Bhaskaranand M, Ramachandra C, Solanki K; EyeArt Study Group. Pivotal evaluation of an artificial intelligence system for autonomous detection of referable and vistion-threatening diabetic retinopathy. JAMA Netw Open 2021 Nov 1;4(11):e2134254.
66. Soares RR, Gopal AD, Parikh D, Shields CN, Patel S, Hinkle J, Sharpe J, Ho AC, Regillo CD, Haller J, Yonekawa Y. Geographic access disparities of clinical trials in neovascular AMD in the US. Am J Ophthalmol 2021;229:160-168.
67. Starr MR, Ryan EH, Obeid A, Ryan C, Gao X, Madhava ML, Maloney SM, Adika AZ, Peddada KV, Sioufi K, Patel LG, Ammar MJ, Forbes NJ, Capone A Jr, Emerson GG, Joseph DP, Eliott D, Regillo CD, Hsu J, Gupta OP, Yonekawa Y, Study Group FTPRDOP. Scleral buckling for primary retinal detachments: Outcomes for scleral tunnels vs. scleral sutures. J Ophthalmic Vis Res 2021;16:377-383.
68. Starr MR, Ammar MJ, Patel LG, Boucher N, Yonekawa Y, Garg SJ, Hsu J, Ho AC, Regillo CD, Chiang A. Comparative incidence of postoperative hemorrhage in vitreoretinal surgery in patients on anti-coagulants. Ophthalmic Surg Lasers Imaging Retina 2021;52:374-379 [Epub Jul 1]
69. Ammar MJ, Wu CW, Starr MR, Regillo CD. Central retinal ein occlusion after laparoscopic sleeve gastrectomy in a 18-year-old female. Am J Ophthalmol Case Rep 2021;21:23 [epub Jul 21]
70. Anaya J, Regillo CD, Haller JA. Cost analysis of routine vitrectomy. Ophthalmology Retina 2021;5:e8-e9.
71. Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo CD, Chakravarthy U. Vortex vein anastomoses and pachychoroid-an evolving understanding. Eye 2021;35:1545-1547.
72. Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo CD, Chakravarthy U. Terms non-exudative and non-neovascular: awaiting entry at the doors of AMD reclassification. Graefes Arch Clin Ophthalmol 2021;259:1381-1383.
73. Starr MR, Obeid A, Gao X, Ryan EH, Shah GK, Ryan C, Madhava ML, Maloney SM, Adika AZ, Peddada KV, Sioufi K, Ammar M, Patel LG, Forbes NJ, Capone A Jr, Emerson GG, Joseph DP, Eliott D, Regillo CD, Hsu J, Gupta OP, Yonekawa Y; Primary Retinal Detachment Outcomes (PRO) Study Group. Prophylactic internal limiting membrane peeling during rhegmatogenous retinal detachment repair. Acta Ophthalmol 2021 Jun;99:e619-e620.
74. Khanani AM, Callanan D, Dreyer R, Chen S, Howard JG, Hopkins J, Lin C, Lorenz-Candlin M, Makadia S, Patel S, Tam T, Gune S, Ladder investigators. End-of-Study results for the ladder phase 2 trial of the port delivery system with ranobizumab for neovascular AMD. Ophthalmology Retina 2021;5:775-787.
75. Starr MR, Obeid A, Ryan EH, Ryan C, Ammar M, Patel LG, Forbes NJ, Capone A Jr, Emerson GG, Joseph DP, Eliott D, Gupta OP, Regillo CD, Hsu J, Yonekawa Y; Primary Retinal Detachment Outcomes (PRO) Study Group. Retinal detachment with inferior retinal breaks: Primary vitrectomy versus vitrectomy with scleral buckle (PRO study report No. 9) Retina 2021;41:525-530 [Epub ahead of print Mar 1]
76. Soares RR, Gopal AD, Parikh D, Shields CN, Patel S, Hinkle J, Sharpe J, Ho AC, Regillo CD, Haller J, Yonekawa Y. Geographic access disparities of clinical trials in neovascular age-related macular degeneration in the United States. Am J Ophthalmol 2021;229:160-168 [Epub ahead of print Apr 10]
77. Starr MR, Yonekawa Y, Obeid A, Ryan EH, Ryan C, Ammar M, Patel LG, Forbes NJ, Capone A Jr, Emerson GG, Joseph DP, Eliott D, Regillo CD, Hsu J, Gupta OP, Kuriyan AE; Primary Retinal Detachment Outcomes (PRO) Study Group. Comparison of visual and anatomic outcomes following RRD surgery using 23-gauge versus 25-gauge vitrectomy: PRO Study Rport No. 12. Ophthalmic Surg Lasers imaging Retina 2021;52:70-76.
78. McClard CK, Wang R, Windham V, Munoz J, Gomez S, Fried S, Saroj N, Regillo C, Wykoff CC, Strutt AM. Questionnaire to assess life impact of treatment by intravitreal injections (QUALITII): Development of a patient-reported measure to assess treatment burden of repear intravitreal injections. BMJ Open Ophthalmol 2021 Apr 7;6:e000669.
79. Starr MR, Cai L, Obeid A, Ryan EH, Eliott D, Ryan C, Forbes NJ, Ammar M, Patel LG, Capone A, Emerson GG, Joseph DP, Gupta OP, Regillo CD, Hsu J, Yonekawa Y; Primary Retinal Detachment Outcomes (PRO) Study Group. Risk factors for presence of cystoid macular edema following rhegmatogenous retinal detachment surgery. Curr Eye Res 2021;May 21:1-9.
80. Borkar DS, Berrocal MH, Rahimy E, Xu D, Regillo CD. Macula mobiozation with a flexible nitinol loop for chronic or recurrent macular holes. Ophthlamology Retina 2021;5:1056-1058 [Epub ahead of print Apr 20]
81. Kuley B, Storey PP, Wibbelsman TD, Pancholy M, Zhang QE, Sharpe J, Bello N, Obeid A, Regillo C, Kaiser RS, Chiang A, Fineman MS, Vander JF, Gupta OP, Spirn MJ, Dunn JP, Mehta S, Park CH, Maguire JI, Garg S. Resolution of pseudophakic cystoid macular edema: 2 mg intravitreal triamcinolone acetonide versus 40 mg sub-tenon triamcinolone acetonide. Curr Eye Res 2021;46:824-830. [Epub ahead of print Jan 31, 2021]
82. Patel SN, Starr MR, Obeid A, Ryan EH, Ryan C, Forbes NJ, Soares RR, Ammar M, Patel LG, Capone A Jr, Emerson GG, Joseph DP, Eliott D, Regillo CD, Gupta OP, Hsu J, Yonekawa Y; Primary Retinal Detachment Outcomes (PRO) Study Group. Characteristics and surgical outcomes of rhegmatogenous retinal detachments in older adults: a multicenter comparative cohort study. Retina 2021;41:947-956 [Epub ahead of print Aug 25, 2020]
83. Starr MR, Hsu J, Yonekawa Y, Mittra RA, Ryan C, Forbes NJ, Ammar M, Patel LG, Obeid A, Capone A Jr, Emerson GG, Joseph DP, Eliott D, Gupta OP, Regillo CD, Ryan EH; Primary Retinal Detachment Outcomes (PRO) Study Group. Surgical techniques for primary rhegmatogenous retinal detachments between surgeons with high versus low single surgery success rates. Acta Ophthalmol 2021;99:1501-1508 [Epub ahead of print Mar 15]
84. Gopal AD, Wallach JD, Shah SA,Regillo C, Ross JS. On-label and off-label clinical studies of FDA-approved ophthalmic therapeutics. Ophthalmology 2021;128:332-334 [Epub ahead of print Jul 16]
85. Patel LG, Peck T, Starr MR, Ammar MJ, Khan MA, Yonekawa Y, Klufas MA, Regillo CD, Ho AC, Xu D. Clinical presentation of rhegmatogenous retinal detachment during the COVID-19 pandemic: A historical cohort study. Ophthalmology 2021;128:686-692 [Epub ahead of print Oct 12, 2020]
86. Patel SN, Tang PH, Storey PP, Wolfe JD, Fein J, Shah SP, Chen E, Abbey A, Ferrone PJ, Shah CP, Liang MC, Stem MS, Khan MA, Yonekawa Y, Garg SJ; Members of the Post Injection Endophthalmitis Study Group. The influence of universal face mask use on endophthalmitis risk after intravitreal anti-VEGF injections during COVID-19 pandemic Ophthalmology 2021 [Epub ahead of print May 18]
87. Sharma A, Kumar N, Singh S, Regillo CD, Freund KB. Management of fluid in neovascular age-related macular degeneration: To mop it, to dab it, or to leave it? Retina 2020;40:1451-1455.
88. Patel D, Borkar DS, Madhava M, Obeid A, Mellen PL, Regillo CD, Garg SJ; Wills Eye Retinal Detachment Study Group. Incidence of management changes at the postoperative day one visit after pars plana vitrectomy for retinal detachment. Am J Ophthalmol 2021;222:271-276 [Epub ahead of print Sep 28, 2020]
89. Sharma A, Parachuri N, Kumar N, Bandello F, Kupperman BD, Loewenstein A, Regillo C, Chakravarthy U. Fluid-based prognostication in n-AMD: Type 3 neovascularization needs an analysis in isolation. Br J Ophthalmol 2021:105:297-298 [Epub ahead of print Dec 8, 2020]
90. Patel S, Mahmoudzadeh R, Salabati M, Soares R, Hinkle J, Hsu J, Garg S, Regillo CD, Ho AC, Cohen MN, Khan MA, Yonekawa Y, Chiang A, Gupta O, Kuriyan A. Bacterial dispersion associated with various patient face mask design during simulated intravitreal injections. Am J Ophthalmol 2021;223:178-183. [Epub ahead of print Oct 28, 2020]
91. Sharma A, Kumar N, Parachuri N, Kupperman BD, Bandello F, Regillo CD, Boyer D, Nguyen QD. Brolucizumab-forseeable workflow in the current scenario. Eye (Lond) 2021;35:1548-1550 [Epub ahead of print Feb 2]
92. Sharma A, Parachuri N, Kumar N, Bandello F, Kupperman BD, Loewenstein A, Regillo CD, Chakravarthy U. Terms non-exudative and non-neovacular: awaiting entry at the doors of AMD reclassification. Graefes Arch Clin Exp Ophthalmol 2021;251:1381-1383 [Epub ahead of print Mar 21]
93. Wang JC, Ryan EH, Ryan C, Kakulavarapu SA, Mardis PJ, Rodriguez M, Stefater JA, Forbes NJ, Gupta O, Capone A, Yonekawa Y, Primary Retina Detachment Outcomes (PRO) Study Group. Factors associated with the use of 360-degree laser retinopexy during primary vitrectomy with or without scleral buckle for rhegmatogenous retinal detachment and impact on surgical outcomes (Pro Study Report Number 4). Retina 2020;40:2070-2076.
94. Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Regillo CD, Boyer D, Nguyen QD. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or Occam’s razor. Ocul Immunol Inflamm 2021;May 20:1-3.
95. Matsunaga D, Su D, Sioufi K, Odeid A, Wibbelsman T, Ho A, Regillo C. The timing of large submacular hemorrhage secondary to age-related macular degeneration relaive to anti-VEGF therapy. Ophthalmol Retina 2021;5: 342-347 [Epub ahead of print Aug 4, 2020]
96. Patel SN, Hsu J, Sivalingam MD, Chiang A, Kaiser RS, Mehta S, Park CH, Regillo CD, Sivalingam A, Vander JF, Ho AC, Garg SJ; Wills Post-Injection Endophthalmitis (PIE) Study Group. The impact of physician face mask use on endophthalmitis after intravitreal injection of vascular endothelial growth factor injections. Am J Ophthalmol 2021;222:194-201 [Epub ahead of print Sep 1, 2020]
97. Starr MR, Obeid A, Ryan EH, Gao X, Matsunaga D, Madhava ML, Maloney SM, Adika AZ, Peddada KV, Sioufi K, Ammar M, Patel LG, Ryan C, Forbes NJ, Capone A Jr, Emerson GG, Joseph DP, Eliott D, Regillo CD, Hsu J, Yonekawa Y, Gupta OP; Primary Retinal Detachment Outcomes (PRO) Study Group. Surgical outcomes of primary RRD with and without concurrent full-thickness macular hole (PRO Study Report No. 7). Ophthalmic Surg Lasers Imaging Retina 2020;51:500-505.
98. Xu D, Levin HJ, Garrigan H, Wibbelsman TD, Obeid A, Pandit RR, Jenkins TL, Mehta S, Ho AC, Hsu J, Regillo CD. Outcomes and complications of in-office laser demarcation of peripheral rhegmatogenous retinal detachments. Ophthalmic Surg Lasers Imaging Retina 2020;51:428-434.
99. Mellen PL, Obeid A, Wibbelsman TD, Hsu J, Konkoly MA, Velez MR, Calem DB, Sioufi K, Jenkins TL, Xu D, Chiang A, Gupta OP, Spirn M, Regillo CD, Ho AC, Klufas MA. Clinical outcomes of eyes with diabetic macular edema switched from aflibercept to ranibizumab. Ophthalmic Surg Lasers Imaging Retina 2020;51:691-697.
100.             Starr MR, Obeid A, Gao X, Ryan EH, Shah GK, Ryan C, Madhava ML, Maloney SM, Adika AZ, Peddada KV, Sioufi K, Ammar M, Patel LG, Forbes NJ, Capone A Jr, Emerson GG, Joseph DP, Eliott D, Regillo CD, Hsu J, Gupta OP, Yonekawa Y; Primary Retinal Detachment Outcomes (PRO) Study Group. Prophylactic internal limiting membrane peeling during rhegmatogenous retinal detachment surgery. Acta Ophthalmol 2021;99:610-620 [Epub ahead of print Aug 4 2020]
101.             Sharma A, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo CD. Brolucizumab: the road ahead. Br J Ophthalmol 2020;104:1631-1632 [Epub ahead of print Aug 22, 2020]
102.             Kuley B, Storey PP, Pancholy M, Wibbelsman TD, Obeid A, Regillo C, Garg S. Treatment of eyes with diabetic macular edema that had a suboptimal response to antivascular endothelial growth factor therapy: 2 mg intravitreal triamcinolone acetonide vs. 0.7 mg dexamethasone implant. J VitreoRetinal Dis 2020;4:372-376.
103.             Ali FS, Jenkins TL, Boparai RS, Obeid A, Ryan ME, Wibblesman TD, Chiang A, Garg SJ; Post-Injection Endophthalmitis Study Group. Aqueous chlorhexidine compared to povidone-iodine as ocular antisepsis before intravitreal injection: A randomized clinical trial. Ophthalmol Retina 2021;5:788-796 [Epub ahead of print Nov 20, 2020]
104.             Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo CD, Chakravarthy U. Notion of tolerating subretinal fluid in neovascular AMD: Understanding the fine prints before the injection pause. Br J Ophthalmol 2021;105:149-150 [Epub ahead of print Sep16, 2020]
105.             Ammar MJ, Hsu J, Chiang A, Ho AC, Regillo CD. Age-related macular degeneration: A review. Curr Opin Ophthalmol 2020;20:215-221.
106.             Kuley B, Storey PP, Pancholy M, Bello N, Murphy J, Goodman J, Wibbelsman ZTD, Obeid A, Regillo C, Garg S. Ocular hypertension following 40 mg sub-Tenon triamcinolone versus 0.7 mg dexamethasone implant versus 2 mg intravitreal triamcinolone. Can J Ophthalmol 2020;55:480-485 [Epub ahead of print Aug 24, 2020]
107.             Hsu J, Regillo CD. Poorer outcomes in real-world studies of anti-VEFG therapy for neovascular AMD. Ophthalmology 2020;127:1189-1190.
108.             Ryan EH, Joseph DP, Ryan CM, Forbes NJK, Yonekawa Y, Mittra RA, Parke DW, Ringeisen A, Emerson GG, Shah GK, Blinder KJ, Capone A, Williams GA, Eliott D, Gupta OP, Hsu J, Regillo CD. Primary retinal detachment outcomes study: Methodology and overall outcomes- Primary retinal detachment outcomes study report number 1. Ophthalmol Retina 2020;8:814-822 [Epub ahead of print Mar 4]
109.             Joseph DP, Ryan EH, Ryan CM, Forbes NJK, Wagely S, Yonekawa Y, Mittra RA, Parke DW, Emerson GG, Shah GK, Blinder KJ, Capone A, Williams GA, Eliott D, Gupta OP, Hsu J, Regillo CD. Primary retinal detachment outcomes study (PRO Study): Pseudophakic retinal detachment outcomes-PRO study report number 3. Ophthalmology 2020;117:1507-1514 [Epub ahead of print May 8]
110.             Ryan EH, Ryan CM, Forbes NJ, Yonekawa Y, Wagley S, Mittra RA, Parke DW, Joseph DP, Emerson GG, Shah GK, Blinder KJ, Capone A, Williams GA, Eliott D, Gupta OP, Hsu J, Regillo CD. Primary retinal detachment outcomes study report number 2: Phakic retinal detachment outcomes. Ophthalmology 2020;127:1077-1085 [Epub ahead of print Mar 9]
111.             Tieger MG, Rodriguez M, Wang JC, Obeid A, Ryan C, Gao X, Kakulavarapu S, Mardis PJ, Madhava ML, Maloney SM, Adika AZ, Peddada KV, Sioufi K, Stefater JA, Forbes NJ, Capone A Jr, Emerson GG, Joseph DP, Regillo C, Hsu J, Gupta O, Eliott D, Ryan EH, Yonekawa Y. Impact of contact versus non-contact wide-angle viewing systems on outcomes of primary retinal detachment repair (PRO study report number 5). Br J Ophthalmol 2021;105:410-413 [Epub ahead of print May 14, 2020]
112.             Lee CS, Hong B, Kasi S, Aderman C, Talcott K, Adam M, Yue B, Akileswaran L, Nakamichi K, Wy Y, Rezaei KA, Olmos de Koo LC, Chee YE, Lee AY, Garg SJ, Van Gelder Rn, Endophthalmitis Study Group. Prognostic utility of whole genome sequencing and polymerase chain reaction tests of ocular fluids in post-procesdural endophthalmitis. Am I Ohpthalmol 2020 [Epub ahead of print Mar 23]
113.             Kuley B, Storey PP, Pancholy M, Obeid A, Murphy J, Goodman J, Wibbelsman TD, Regillo C, Chiang A. Ocular hypertension following intravitreal injection of 0.7 mg dexamethasone implant versus 2 mg triamcinolone. Semin Ophthalmol 2020;35:141-146.
114.             Ammar MJ, Hsu J, Chiang A, Ho AC, Regillo CD. Age-related macular degeneration therapy: A review. Curr Opin Ophthalmol 2020;31:215-221.
115.             Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, Regillo CD. Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD). Eye (Lond) 2020;34:1310-1312 [Epub ahead of print Mar 4]
116.             Sharma A, Hafeez Faridi M, Kumar N, Parachuri N, Sharma R, Kuppermann BD, Bandello F, Loewenstein A, Regillo CD. Immunogenicity and efficacy after switching from original ranibizumab to a ranibizumab biosimilar: real-world data. Eye (Lond) 2020;34:1008-1009. [Epub ahead of print Dec 16, 2019]
117.             Patel SN, Wu C, Obeid A, Sivalingam M, Gervasio K, Wibbelsman TD, Levin H, Xu D, Regillo CD, Hsu J, Ho AC. Sociodemographic factors in neovascular age-related macular degeneration. Ophthalmology 2020;127:280-282. [Epub ahead of print Oct 14, 2019]
118.             Deaner JD, Aderman CM, Bonafede L, Regillo CD. PPV, retinectomy, and silicone oil without scleral buckle for recurrent RRD from proliferative vitreoretinopathy. Ophthamic Surg Lasers Imaging Retina 2019;50:278-287.
119.             Chen Y, Shah GK, Shah V, Blinder KJ, Jeroudi AM, Leonard A, Gilca M, Pollack JS, Wang R, Wykoff CC, Weinstock BM, Regillo CD, Van Zyl T, Modjtahedi BS, Eliott D, Kalevar A, Jumper JM, Whitted RJ, Lee G, Kitchens JW, Joseph A, Heier JS, Rostamizadeh M, Abdelaziz M, Singerman LJ, Hu JK, Tewari A. Outcomes and practice preferences after endophthalmitis following anti-VEGF intravitreal injection. J Vitreoretinal Dis 2019;3:411-419.
120.             Sharma A, Parachuri N, Kumar N, Kuppermann BD, Bandello F, Loewenstein A, Regillo CD. Subfoveal neurosensory retina flattening and observe (SNF-Ob): A novel approach in diabetic macular edema management: A potential cost-effective strategy to be explored. Ophthalmol Retina 2019;11:1009-1011 [Epub ahead of print Jul 10]
121.             Borkar DS, Wibbelsman TD, Buch PM, Rapuano SB, Obeid A, Ho AC, Hsu J, Regillo CD, Ayres BD, Hammersmith KM, Nagra PK, Rapuano CJ, Syed ZA. Endophthalmitis rates and clinical outcomes following penetrating and endothelial keratoplsty. Am J Ophthalmol 2019;205:82-90 [Epub ahead of print May 10]
122.             Sharma A, Kumar N, Parachuri N, Kupperman BD, Bandello F, Regillo CD. Ranibizumab port delivery system (RPDS): Realising long awaited dream of prolonged VEGF suppression. Eye (Lond) 2020;34:422-423 [Epub ahead of print Jun 5, 2019]
123.             Bakri SJ, Wolfe JD, Regillo CD, Flynn HW, Wykoff CC. Evidence-based guidelines for management of diabetic macular edema. J Vitreoretinal Dis 2019;3:145-152.
124.             Shields RA, Tang PH, Regillo CD, Silva RA. Displacement of submacular hemorrhage with subretinal injection of recombinant tissue plasminogen activator and gas tamponade in the setting of myopic degeneration. Ophthalmic Surg Lasers Imaging Retina 2019;50:257-259.
125.             Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, Chiang Y, Ehrlich JS, Erickson S, Hanley WD, Horvath J, Maass KF, Singh N, Tang F, Barteselli G. The port delivery system with ranibizumab for noevascular age-related macular degeneration: Reuslts from the randomized phase 2 ladder clinical trial. Ophthalmology 2019;126:1141-1154 [Epub ahead of print Apr 1]
126.             Talcott KE, Obeid A, Gao X, Adika A, Regillo CD. Pars plana vitrectomy alone for primary rhegmatogenous retinal detachments associated with inferior breaks in phakic eyes. Ophthalmic Surg Lasers Imaging Retina 2019;50:153-158.
127.             Aderman CM, Rahimy E, Obeid A, Gao X, Hsu J, Garg SJ, Regillo CD, Gupta OP, Chiang A. Comparing 33-gauge versus 30-gauge needles for intravitreal injections. Ophthalmol Retina 2018;2:1078-1079
128.             London NJS, Kaiser RS, Khan MA, Alshareef RA, Khuthaila M, Shahlaee A, Obeid A, London VA, DeCroos FC, Gupta OP, Hsu J, Vander JF, Spirn MJ, Regillo CD. Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial. Br J Ophthalmol. 2019;103:1306-1313 [Epub ahead of print Oct 31, 2018]
129.             Storey PP, Obeid A, Pancholy M, Goodman J, Borkar D, Su D, Regillo CD. Ocular hypertension after intravitreal injection of 2-mg triamcinolone. Retina 2020;40:75-79 [Epub ahead of print Oct 9, 2018]
130.             Borkar DS, Obeid A, Su DC, Storey PP, Gao X, Regillo CD, Kaiser RS, Garg SJ, Hsu J. Endophthalmitis Rates After Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol 2018;194:1-6 [Epub ahead of print Sep 28]
131.             Yu JJ, Agrón E, Clemons TE, Domalpally A, van Asten F, Keenan TD, Cukras C, Chew EY; Age-Related Eye Disease Study 2 Research Group. Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17. Ophthalmology 2019;126:261-273 [Epub ahead of print Aug 22, 2018]
132.             Obeid A, Su D, Patel SN, Uhr JH, Borkar D, Gao X, Fineman MS, Regillo CD, Maguire JI, Garg SJ, Hsu J. Outcomes of Eyes Lost to Follow-Up with Proliferative Diabetic Retinopathy that received Panretinal Photocoagulation vs Intravitreal Anti-Vascular Endothelial Growth Factor. Ophthalmology 2019;126:407-413 [Epub ahead of print Aug 2, 2018]
133.             Keenan TD, Agrón E, Domalpally A, Clemons TE, van Asten F, Wong WT, Danis RG, Sadda S, Rosenfeld PJ, Klein ML, Ratnapriya R, Swaroop A, Ferris FL 3rd, Chew EY; AREDS2 Research Group. Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16. Ophthalmology 2018;125:1913-1928 [Epub ahead of print Jul 27]
134.             Borkar DS, Obeid A, Su DC, Gao X, Regillo CD, Kaiser RS, Garg SJ, Hsu J, Post injection endophthalmitis (PIE) study group. Endophthalmitis rates after bilateral same day intravitreal anti-vascular endopthelial growth factor injections. Am J Ophthalmol 2018;194:1-6 [Epub ahead of print Jul 5]
135.             Sridhar J, Kasi S, Paul J, Shahlaee A, Rahimy E, Chiang A, Spirn MJ, Hsu J, Garg SJ, Retina Service of Wills Eye Hospital Viterctomy Study Group. A prospective, randomized trial comparing plain gut to polyglactin 910 sutures for sclerotomy closure after 23-gauge pars plana vitrectomy. Retina 2018;38:1216-1219.
136.             Daniel E, Pan W, Ying G, Kim BJ, Grunwald JE, Ferris FL, Jaffe GJ, Toth CA, Martin DF, Fine SL, Maguire MG, Comparison of age-related macular degeneration treatment trials group. Development and course of scars in the comparison of age-related macular degeneration treatment trials. Ophthalmology 2018;125:1037-1046.
137.             Rayess N, Rahimy E, Ying GS, Pefkianaki M, Franklin J, Regillo CD, Ho AC, Hsu J. Baseline choroidal thickness as a chort-term predictor of visual acuity improvement following antivascular endothelial growth factor therapy in branch retinal vein occlusion. Br J Ophthalmol 2019;103:55-59 [Epub ahead of print Mar 22, 2018]
138.             Holz FG, Sadda SR, Busbee B, et al for the Chroma and Spectri Study Investigators. Effiacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri Phase 3 randomized clinical trials. JAMA Ophthalmology 2018;136:398-403 [Epub ahead of print May 2]
139.             Khan MA, Gupta OP, Pendi K, Chiang A, Vander J, Regillo CD, Hsu J. Pars plana vitrectomy with anterior chamber versus gore-tex sutured posterior chamber intraocular lens placement: long-term outcomes. Retina 2019;39: 860-866 [Epub ahead of print Jan 16, 2018]
140.             Scott IU, VanVeldhuisen PC, Ip MS, et al. Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who respond well to anti-vascular endothelial growth factor medications: Secondary outcomes from the SCORE2 randomized clinincal trial. JAMA Ophthalmology 2018;136:337-345.
141.             Khan MA, Kuley A, Riemann CD, Berrocal MH, Lakhanpal RR, Hsu J, Sivalingam A, Ho AC, Regillo CD. Long-term visual outcomes and safety profile of 27-gauge pars plana vitrectomy for posterior segment disease. Ophthalmology 2018;125:423-431 [Epub ahead of print Nov 13, 2017]
142.             Van Asten F, Simmons M, Singhal A, Keenan TD, Ratnapriya R, Agrón E, Clemons TE, Swaroop A, Lu Z, Chew EY; Age-Related Eye Disease Study 2 Research Group. A deep phenotype association study reveals specific phenotype associations with genetic variants in age-related macular degeneration: Age-related eye disease study 2 (AREDS2) report no. 14. Ophthalmology 2018;125:559-568 [Epub ahead of print Oct 30, 2017]
143.             Yaspan BL, Williams DF, Holz FG, Regillo CD, Li Z, Dressen A, van Lookeren Campagne M, Le KN, Graham RR, Beres T, Bhangale TR, Honigberg LA, Smith A, Henry EC, Ho C, Strauss EC; MAHALO Study Investigators. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci Transl Med 2017 Jun 21:9(395)
144.             DeCroos FC, Reed D, Adam MK, Salz D, Gupta OP, Ho AC, Regillo CD. Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial. Am J Ophthalmol 2017;180:142-150. [Epub ahead of print Jun 15]
145.             Regillo CD, Callanan DG, Do DV, Fine HF, Holekamp NM, Kuppermann BD, Singer MA, Singh RP. Use of corticosteroids in the treatment of patients with diabetic macular edema who have suboptimal response to anti-VEGF: Recommendations of an expert panel. Ophthalmic Surg Lasers Imaging Retina 2017;48:291-301.
146.             Wittenborn JS, Clemons T, Regillo C, Rayess N, Liffmann Kruger D, Rein D. Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System. JAMA Ophthalmol 2017;135:452-459.
147.             Khan MA, Durrani AK, Hsu J, Regillo CD. 27-gauge vitrectomy wound integrity: A Randomized Pilot Study Comparing Angled Versus Straight Entry in Fluid-Filled Vitrectomized Eyes. Retina 2018:38;678-683 [Epub ahead of print Mar 29, 2017]
148.             Rahimy E, Rayess N, Brady CJ, Regillo CD. Treat-and-extend regimen for macular edema secondary to central retinal vein occlusion: 12 month results. Ophthalmology Retina 2017;1:118-123.
149.             Ho AC, Albini TA, Brown DM, Boyer DS, Regillo CD, Heier JS. The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good. JAMA Ophthalmol. 2017 Mar 1;135(3):268-273
150.             Cohen MN, Houston SK, Juhn A, Ho AC, Regillo CD, Vander J, Chiang A. Effects of aflibercept on refractory macular edema associated with central retinal vein occlusion. Can J Ophthalmol 2016 Oct;51(5):342-347.
151.             Shields CL, Say EA, Pefkianaki M, Regillo CD, Caywood EH, Jabbour PM, Shields JA. Rhegmatogenous retinal detachment after intraarterial chemotherapy for retinoblastoma: The 2016 Founders Award Lecture. Retina 2017;37:1441-1450 [Epub ahead of print Oct 26]
152.             Rayess N, Rahimy E, Ying GS, Pefkianaki M, Franklin J, Regillo CD, Ho AC, Hsu J. Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion. Am J Ophthalmol 2016;171:47-52.
153.             Adam MK, Thornton S, Regillo CD, Park C, Ho AC, Hsu J. Minimal endoillumination levels and display luminous emittance during three-dimensional heads-up vitreoretinal surgery. Retina. 2017;37:1746-1749. [Epub ahead of print Nov 29]
154.             Jackson TL, Regillo CD, Girach A, Dugel PU; MIVI-TRUST Study Group. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin. Ophthalmic Surg Lasers Imaging Retina 2016 Aug 1;47(8):716-23.
155.             Da Cruz L, Dorn JD, Humayun MS, Dagnelie G, Handa J, Barale PO, Sahel JA, Stanga PE, Hafezi F, Safran AB, Salzmann J, Santos A, Birch D, Spencer R, Cideciyan AV, de Juan E, Duncan JL, Eliott D, Fawzi A, Olmos de Koo LC, Ho AC, Brown G, Haller J, Regillo C, Del Priore LV, Arditi A, Greenberg RJ; Argus II Study Group. Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial. Ophthalmology 2016;123:2248-54. [Epub ahead of print Jul 19]
156.             Shieh WS, Sridhar J, Hong BK, Maguire JI, Rahimy E, Shahlaee A, Ho AC, Hsu J, Regillo CD, Chiang A. Ophthalmic Complications Associated with Direct Oral Anticoagulant Medications. Semin Ophthalmol. 2016;Jul:1-6
157.             Wykoff CC, Elman MJ, Regillo CD, Ding B, Lu N, Stoilov I. Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials. Ophthalmology. 2016; Aug;123(8):1716-21 [Epub May 18, 2016]
158.             Moshfeghi DM, Kaiser PK, Michels S, Midena E, Kitchens JW, Prenner JL, Regillo CD, Reichel E. The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2016 Jun;47(6 Suppl):S4-S14
159.             Rahimy E, Shahlaee, Khan MA, Ying G, Maguire JI, Ho AC, Regillo CD, Hsu J. Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 2016;164:118-127 [Epub Dec 31 2015]
160.             Greven MA, Garg S, Chiu B, Shah SP, Wolfe J, Fine HF, Roth DB, Robinson J, Mong J, Hsu J, Regillo C, Ho A, Haller JA. Vitrectomy After ocriplasmin for vitreomacular adhesion Or Macular hole (VAVOOM) study. Br J Ophthalmol 2015 Dec 9. [Epub ahead of print]
161.             Zhou Q, Daniel E, Maguire MG, Grunwald JE, Martin ER, Martin DF, Ying GS, on behalf of the Comparison of Age-related Macular Degeneration Treatment Trials Research Group. Pseudodrusen and incidence of late age-related macular degeneration in fellow eyes in the comparison of age-related macular degeneration treatment trials. Ophthalmology 2016;123;1530-1540.
162.             Rahimy E, Rayess N, Ho Ac, Regillo CD. Treatment outcomes for neovascular age-related macular degeneration patients with initial vision better than 20/40 using a treat-and-extend regimen. Retina 2016;36:875-880. [Epub Dec 1, 2015]
163.             AREDS2 Research Group, Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Sperduto RD, Ferris FL 3rd, Chew EY. The Association of Statin Use with Cataract Progression and Cataract Surgery: The AREDS2 Report Number 8. Ophthalmology. 2016 Apr;123(4):916-7. [Epub 2015 Dec 11]
164.             Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E, for the Comparison of Age-related Macular Degeneration Treatment Trials Research Group. Angiographic cystoid macular edema and outcomes in the Comparison of Age-related Macular Degeneration Treatment Trials. Ophthalmology 2016;123:858-864.
165.             Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG, for the Comparison of Age-related Macular Degeneration Treatment Trials Research Group. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-related Macular Degeneration Treatment Trials. Ophthalmology 2016;123:609-616.
166.             Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ, for the Comparison of Age-related Macular Degeneration Treatment Trials Research Group. Macular morphology and visual acuity in the second year of the Comparison of Age-related Macular Degeneration Treatment Trials. Ophthalmology 2016;123:865-875.
167.             Khan MA, Shahlaee A, Toussaint B, Hsu J, Sivalingam A, Dugel PU, Lakhanpal RR, Riemann CD, Berrocal MH, Regillo CD, Ho AC. Outcomes of 27 Gauge Microincision Vitrectomy Surgery for Posterior Segment Disease. Am J Ophthalmol 2016;161:36-43.
168.             Maguire MG, Ying G, Jaffe GJ, Toth CA, Daniel E, Grunwald JE, Martin DF, Hagstrom SA, for the CATT Research Group. Single-nucleotide polymorphisms associated with age-related macular degeneration and lesion phenotypes in the comparison of age-related macular degeneration treatment trials. JAMA Ophthalmology 2016;134:647-681.
169.             Ying G, Maguire MG, Daniel E, Grunwald JE, Ahmed O, Martin DF, Age-Related Macular Degeneration Treatment Trials Research Group. Association between antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in the comparison of age-related macular degeneration treatment trials. Ophthalmology 2016;123:352-360.
170.             Garg SJ, Dollin M, Storey P, Pitcher JD, Fang-Yen NH, Vander J, Hsu J, The Post-Injection Endopthalmitis Study Team. Microbial spectrum and outcomes of endophthalmitis after intravitreal injection versus pars plana vitrectomy. Retina 2016;36:351-359.
171.             Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA 3rd; American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. JAMA Ophthalmol 2015: 29:1-6.
172.             Regillo CD, Busbee BG, Ho AC, Ding B, Haskova Z. Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration. Am J Ophthalmol 2015;160:1014-1023.
173.             Setlur VJ, Rayess N, Garg SJ, Hsu J, Luo CK, Regillo CD, Fineman MS, Sivalingam A. Combined 23-Gauge PPV and Scleral Buckle Versus 23-Gauge PPV Alone for Primary Repair of Pseudophakic Rhegmatogenous Retinal Detachment. Ophthalmic Surg Lasers Imaging Retina 2015 Jul 1;46(7):702-7.
174.             Ho AC, Humayun MS, Dorn JD, da Cruz L, Dagnelie G, Handa J, Barale PO, Sahel JA, Stanga PE, Hafezi F, Safran AB, Salzmann J, Santos A, Birch D, Spencer R, Cideciyan AV, de Juan E, Duncan JL, Eliott D, Fawzi A, Olmos de Koo LC, Brown GC, Haller JA, Regillo CD, Del Priore LV, Arditi A, Geruschat DR, Greenberg RJ; Argus II Study Group. Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind. Ophthalmology 2015 Aug;122(8):1547-54.
175.             Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2015 Sep;122(9):1846-1853.
176.             Houston SK 3rd, Rayess N, Cohen MN, Ho AC, Regillo CD. Influence of vitreomacular interface on anti-vascular endothelial growth factor therapy using treat and extend treatment protocol for age-related macular degeneration (VINTREX). Retina 2015;35:1757-64.
177.             Dugel OU, Regillo C, Eliott D. Characterization of anatomic and visual function outcomes in patients with full-thickness macular hole in ocriplasmin phase 3 trials. Am J Ophthalmol 2015;160:94-99.
178.             Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Monés J, Regillo C, Tadayoni R, Talks J, Wolf S. Treat-and-extend regimens with anti-vegf agents in retinal diseases: A Literature Review and Consensus Recommendations. Retina 2015;35:1489-506.
179.             Cuilla TA, Ying GS, Maguire MG, Martin DF, Jaffe GJ, Grunwald JE, Daniel E, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 2015;122(6):1203-11.
180.             Ho AC, Humayan MS, Dorn JD, Da Cruz L, Dagnelie G, Handa J, Barale PO, Sahel JA, Stanga PE, Hafezi F, Safran AB, Salzmann J, Santos A, Birch D, Spencer R, Cideciyan AV, De Juan E, Duncan JL, Eliott D, Fawzi A, Olmos de Koo LC, Brown GC, Haller JA, Regillo CD, Del Priore LV, Arditi A, Geruschat DR, Greenberg RJ, for the Argus study group. Long-term results from an epiretinal prosthesis to restore sigh to the blind. Ophthalmology 2015;122:1547-54.
181.             Boyer D, Freund KB, Regillo C, Levy MH, Garg S. Long-term (60 month) results for the implantable miniature telescope: Efficiacy and safety outcomes stratified by age in patients with end-stage age-related macular degeneration. Clin Ophthalmology 2015;9:1099-1107.
182.             Hagstrom SA, Ying GS, Maguire MG, Martin DF; CATT Research Group, Gibson J, Lotery A, Chakravarthy U; IVAN Study Investigators. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. Ophthalmology 2015;122(8):1563-8.
183.             Rahimy E, Fineman MS, Regillo CD, Spirn MJ, Hsu J, Kaiser RS, Maguire JI, Brown GC, Chiang A. Speculum versus Bimanual Lid Retraction during Intravitreal Injection. Ophthalmology 2015;122(8):1729-30.
184.             Salz DA, Pitcher JD, Hsu J, Regillo CD, Fineman MS, Elliott KS, Vander JF, Fischer DH, Spirn MJ. Oral eplerenone for treatment of chornic central serous chorioretinopathy: A case series. Ophthalmic Surg Laser Imaging Retina 2015;46:439-444.
185.             Rahimy E, Reddy S, DeCroos FC, Khan MA, Boyer DS, Gupta OP, Regillo CD, Haller JA. Prospective evaluation of visual acuity agreement between standard early treatment diabetic retinopathy study chart and a handheld equivalent in eyes with retinal pathology. Retina 2015;35(8):1680-7.
186.             Pitcher JD, Khan MA, Storey PP, Hsiao-Fang-Yen N, Dollin ML, Hsu J, Ho AC, Regillo CD, Garg SJ. Contemporary management of rhegmatogenous retinal detachment due to giant retina tears: A consecutive case series. Ophthalmic Surg Laser Imaging Retina 2015;46:566-570.
187.             Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full thickness macular holes. Am J Ophthalmol 2015;159:861-867.
188.             Meredith TA, McCannel CA, Barr C, Doft BH, Peskin E, Maguire MG, Martin DF, Prenner JL, for the CATT research group. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 2015;122:817-821.
189.             Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF, for the CATT research group. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2015;122:809-816.
190.             Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL, Fine SL, Maguire MG, for the CATT group. Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatment trials (CATT). Ophthalmology 2015;122:391-398.
191.             Schwartz SD, Regillo CD, Lam BI, Eliott D, Rosenfeld PJ, Gregori NZ, Hubschman JP, Davis JL, Jeilwell G, Spirn M, Maguire J, Bateman J, Ostrick EM, Morris D, Vincent M, Anglade E, Del Priore LV, Lanza R. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: Follow-up of two open-label phase 1/2 studies. Lancet 2015;385:509-16 [Epub ahead of print Oct 15, 2014]
192.             Rayess N, Rahimy E, Ying G, Bagheri N, Ho AC, Regillo CD, Vander JF, Hsu J. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol 2015; 159:85-91 [Epub Sep 19, 2014]
193.             Rayess N, Houston SK 3rd, Gupta OP, Ho AC, Regillo CD. Three year treatment outcomes for neovascular AMD using a treat and extend regimen. Am J Ophthalmol 2015;159;3-8 [Epub Sep 8, 2014]
194.             Lee JY, Folgar FA, Maguire MG, Ying GS, Toth CA, Martin DF, Jaffe GJ, for the CATT Research Group. Outer retinal tabulation in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology 2014;121:2423-2431.
195.             DeCroos FC, Todorich B, Alshareef R, Khuthaila M, Fekrat S, Ho AC, Regillo CD, Sprin MJ. Neovascular events in eyes with central retinal vein undergoing serial bevacizumab or ranibizumab intravitreal injections: A retrospective review. J Ophthalmic Vis Res 2014;9:1-8.
196.             Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P; for the HARBOR Study Group. Twenty-four month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2014;121:2181-2192 [Epub ahead of print Jul 9]
197.             Rovner BW, Casten RJ, Hegel MT, Massof RW, Leiby BE, Ho AC, Tasman WS, Wills Eye Study Group. Low vision depression prevention trial in age-related macular degeneration. A randomized clinical trial. Ophthalmology 2014;121:2204-2211.
198.             Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel P, Holz F, Weber M, Danis RP, Kupperman BD, Bailey C, Billman K, Kapik B, Kane, Green K; for the FAME Study Group. Sustained delivery fluocinolone acetonide vitreous implants: Long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014;121:1892-1903.
199.             Ying G, Kim B, Maguire M, Huang J, Daniel E, Jaffe GL, Grunwald AE, Blinder KJ, Flaxel CJ, Rahhal F, Regillo CD, Martin DF; for the CATT Research Group. Sustained visual acuity loss in the comparison of age-related macular degeneration treatment trials (CATT). JAMA Ophthalmology 2014;132:915-921.
200.             Folger FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA,; for the Comparison of Age-related Macular Degeneration Treatment Trials (CATT) Research Group. Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014;121:1956-1965.
201.             Hagstrom SA, Ying G, Pauer GJT, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; for the CATT Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: Comparison of age-related macular degeneration treatment trials (CATT). JAMA Ophthalmol 2014;132:521-527.
202.             Storey P, Alshareef R, Khuthaila M, London N, Leiby B, DeCroos C, Kaiser R; for the Wills PVR Study Group. Pars plana vitrectomy and scleral buckle versus pars plana vitrectomy alone for patients with rhegmatogenous retinal detachment at high risk for proliferative vitreoretinopathy. Retina 2014;34:1945-1951.
203.             Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF; Macula Society CSC Collaborative Study Group, Research and Education Committee and Website Committee. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 2014;121(5):1073-8.
204.             Boyer DS, Yoon YH, Belfort R, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; for the Ozurdex Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2104;121:1904-1914.
205.             Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol 2014;158(1):128-135.
206.             Chang W, Garg SJ, Maturi R, Hsu J, Sivalingam A, Gupta SA, Regillo CD, Ho AC. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration. Am J Ophthalmol 2014;157:1250-1257. [Epub 2014 Feb 13]
207.             Storey P, Dollin M, Pitcher J, Reddy S, Vojtko J, Vander J, Hsu J, Garg SJ. Post-Injection Endophthalmitis Study Team. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology 2014;121:283-9. [Epub 2013 Oct 18]
208.             Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). JAMA Ophthalmol 2014;132(5):521-7.
209.             Do DV, Pieramici D, Van Lookeren Campagne M, Beres T, Friesenhahn M, Zhang Y, Strauss EC, for the Phase IA Investigators. A phase IA dose-escalating study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy. Retina 2014;34:313-320.
210.             Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013;120(9):1860-70.
211.             Danis RP, Domalpally A, Chew EY, Clemons TE, Armstrong J, SanGiovanni JP, Ferris FL 3rd; AREDS2 Study Group. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). Invest Ophthalmol Vis Sci 2013;54(7):4548-54.
212.             Gangaputra S, Lovato JF, Hubbard L, et al for the ACCORD Eye Research Group. Comparison of standardized clinical classification with fundus photograph grading for the assessment of diabetic retinopathy and diabetic macular edema severity. Retina 2013;33:1393-99.
213.             Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120(5):1046-56.
214.             Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013;120(3):593-9.
215.             Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013 Jan;120(1):122-9.
216.             Witkin AJ, London NJ, Wender JD, Fu A, Garg SJ, Regillo CD. Spectral-domain optical coherence tomography of white dot fovea. Arch Ophthalmol 2012;130(12):1603-5.
217.             Bansal AS, Bianciotto CG, Maguire JI, Regillo CD, Shields JA, Shields CL. Safety of pars plana vitrectomy in eyes with plaque-irradiated posterior uveal melanoma. Arch Ophthalmol 2012;130(10):1285-90.
218.             Bansal AS, Hsu J, Garg SJ, Sivalingam A, Vander JF, Moster M, Maguire JI, Regillo CD. Optic neuropathy after vitrectomy for retinal detachment: Clinical features and analysis of risk factors. Ophthalmology 2012;119:2364-2370 [Epub Jul 26]
219.             Chiang A, Garg SJ, Alshareef RA, Pitcher JD 3rd, Hu AY, Spirn MJ, Hsu J, Lane RG, Regillo CD, Ho AC, Schwartz SD. Removal of posterior segment retained lens material using the OZIL phacoemulsification handpiece versus fragmatome during pars plana vitrectomy. Retina 2012;32:2119-2126. [Epub Jun 20]
220.             Barry MP, Dagnelie G; Argus II Study Group. Use of the Argus II retinal prosthesis to improve visual guidance of fine hand movements. Invest Ophthalmol Vis Sci 2012;53(9):5095-101.
221.             CATT Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for neovascular age-related macular degeneration: Two year results. Ophthalmology 2012;119:1338-98.
222.             Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
223.             Humayan MS, Dorn JD, da Cruz L, et al. Interim results from the international trial of second sight’s visual prognosis. Ophthalmology 2012;119:779-788.
224.             Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: Clinical and economic impact. Am J Ophthalmol 2012;153:468-473. (Epub 2011 Oct 11]
225.             Kaiser RS, Gupta OP, Regillo CD, Ho AC, Fineman MS, Vander JF, McNamara JA, Brown GC. Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response. Ophthalmic Surg Lasers Imaging. 2012;43:13-19. (Epub 2011 Oct 13)
226.             Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E, Soubrane G, Kapik B, Billman K, Kane FE, Green K; for the FAME study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-2132.
227.             Orlin A, Hadley D, Chang W, Ho AC, Brown G, Kaiser RS, Regillo CD, Godshalk AN, Lier A, Kaderli B, Stambolian D. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 2012;32:4-9.
228.             Rovner BW, Casten RJ, Massof RW, Leiby BE, Tasman, Wills Eye Study Group. Psychological and cognitive determinants of vision function in age-related macular degeneration. Arch Ophthalmol 2011;129:885-890.
229.             Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011 Dec;118(12):2453-60.
230.             CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011 May 19;364(20):1897-908. Epub 2011 Apr 28.
231.             Shah CO, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA; Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 2011;118:2028-2034.
232.             Rezeq SS, Vander JF, Hsu J, Regillo CD, Ho AC, Garg SJ, Spirn MJ. Iatrogenic retinal breaks. Ophthalmology 2011;118:1696-1697.
233.             Baker PS, Spirn MJ, Chiang A, Regillo CD, Ho AC, Vander JF, Kaiser RS. 23-Gauge transconjunctival pars plana vitrectomy for removal of retained lens material. Am J Ophthalmol 2011;152:624-627.
234.             Campochiaro PA, Brown DM, Pearson A, Cuilla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE; for the FAME study Group. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-635.
235.             Kitei PM, Say EA, Shields CL, Regillo CD, Shields JA. Management of Retinal Vasoproliferative Tumor Associated with ROP by Plaque Brachytherapy. J Pediatr Ophthalmol Strabismus. 2011;48:e10-2.
236.             Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: Clinical and economic impact. Ophthalmology 2010;117:2134-2140.
237.             Chen W, Stambolian D, Edwards AO, Branham KE, Othman M, Jakobsdottir J, Tosakulwong N, Pericak-Vance MA, Campochiaro PA, Klein ML, Tan PL, Conley YP, Kanda A, Kopplin L, Li Y, Augustaitis KJ, Karoukis AJ, Scott WK, Agarwal A, Kovach JL, Schwartz SG, Postel EA, Brooks M, Baratz KH, Brown WL; Complications of Age-Related Macular Degeneration Prevention Trial Research Group, Brucker AJ, Orlin A, Brown G, Ho A, Regillo C, Donoso L, Tian L, Kaderli B, Hadley D, Hagstrom SA, Peachey NS, Klein R, Klein BE, Gotoh N, Yamashiro K, Ferris Iii F, Fagerness JA, Reynolds R, Farrer LA, Kim IK, Miller JW, Cortón M, Carracedo A, Sanchez-Salorio M, Pugh EW, Doheny KF, Brion M, Deangelis MM, Weeks DE, Zack DJ, Chew EY, Heckenlively JR, Yoshimura N, Iyengar SK, Francis PJ, Katsanis N, Seddon JM, Haines JL, Gorin MB, Abecasis GR, Swaroop A. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A 2010;20;107(16):7401-6.
238.             Kaiser RS, Prenner J, Scott IU, Brucker AJ, Flynn HW Jr, Williams GA, Ho AC, Regillo CD, Capone A, Avery R, Eliott D, Dugel P, Pollack J. The Microsurgical Safety Task Force: evolving guidelines for minimizing the risk of endophthalmitis associated with microincisional vitrectomy surgery. Retina 2010;30(4):692-9.
239.Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117(6):1134-1146.
240.             Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY, CRUISE investigators. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary endpoint results of a phase III study. Ophthalmology 2010;117:1124-1133.
241.             Ehlers JP, Spirn MJ, Shah CP, Fenton GL, Baker PS, Regillo CD, Ho AC. Ranibizumab for exudative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors. Ophthalmic Surg Lasers Imaging. 2010;41(2):182-9.
242.Hadley D, Orlin A, Brown G, Brucker AJ, Ho AC, Regillo CD, Donoso LA, Tian L, Kaderli B, Stambolian D. Analysis of six genetic risk factors highly associated with AMD in the region surrounding ARMS2 and HTRA1 on chromosome 10, region q26. Invest Ophthalmol Vis Sci. 2010;51(4):2191-6.
243.Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.
244.             Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, Holland H, Sharma S. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-1399.
245.             Hsu J, Chen E, Gupta O, Fineman, MS, Garg SJ, Regillo CD. Hypotony after 25-gauge vitrectomy using oblique versus direct cannula insertions in fluid-filled eyes. Retina 2008;28:937-940.
246.             Ehlers JP, Kunimoto DY, Ittoop S, Maguire J, Ho AC, Regillo CD. Metallic intraocular foreign bodies: Characteristics, interventions, and prognostic factors for visual outcome and globe survival. Am J Ophthalmol 2008;146-433.
247.             Gupta OP, Ho AC, Kaiser PK, Regillo CD, Chen S, Dyer DS, Dugel PU, Gupta S, Pollack JS. Short-term outcomes of 23-gauge pars plana vitrectomy. Am J Ophthalmol. 2008;146:193-197.
248.             Shah CP, Ho AC, Vander JF, Fineman MS, Brown GC, Regillo CD. Short-term outcomes of 25-gauge vitrectomy with silicone oil for complicated retinal detachment repair. Retina 2008;28:723-728.
249.             Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N; The PIER Study Group. Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year. Am J Ophthalmol 2008;145(2):239-248.
250.             Kunimoto DY, Kaiser RS, Wills Eye Retina Service. Incidence of endophthalmitis after 20- and 25-gauge vitrectomy. Ophthalmology 2007;114:2133-2137.
251.             Hsu J, Kaiser RS, Sivalingham A, Abraham P, Fineman MS, Samuel MA, Vander JF, Regillo CD, Ho AC. Intravitreal bevacizumab (Avastin) in central retinal vein occlusion. Retina 2007;27:1013-1019.
252.             Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular AMD: Applying clinical trials results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-637.
253.             Ehlers JP, Fintak DR, Gupta OP, Regillo CD, Fineman MS, and Ho AC. Pegaptanib for choroidal neovascularization in treatment-naïve exudative age-related macular degeneration. Ophthalmic Surg, Lasers Imaging. 2007;38: 371-377.
254.             Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
255.             Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
256.             Slakter JS, Bochow T, D’Amico DJ, et al (Anecortave Acetate Clincal Study Group). Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006;113:3-13.
257.             Gupta OP, Weichel ED, Regillo CD, Fineman MS, Kaiser RS, Ho AC, McNamara JA, Vander JF. Postoperative complications associated with 25-gauge pars plana vitrectomy. Ophthalmic Surg Lasers Imaging 2007;38;270-275.
258.             Scartozzi R, Bessa AS, Gupta OP, Regillo CD. Intraoperative sclerotomy-related retinal breaks for macular surgery, 20 vs. 25-gauge vitrectomy systems. Am J Ophthalmol 2007;143:155-156.
259.             Chhabra S, Kunimoto DY, Kazi L, Regillo CD, Ho AC, Belmont J, Maguire J, Vander, Brown GC. Endophthalmitis after open globe injury: Microbiologic spectrum and susceptibilities of isolates. Am J Ophthalmol 2006;142:852-854.
260.             Hurley BR, McNamara JA, Fineman MS, Ho AC, Tasman W, Kaiser RS, Vander JF, Regillo CD, Brown GC. Laser treatment for retinopathy of prematurity: Evolution in treatment technique over 15 years. Retina 2006;26:S16-17.
261.             Garg SJ, Regillo CD, Aggarwal S, Bilyk JR, Savino PJ. Macular exudative retinal detachment in a patient with a dural cavernous sinus fistula. Arch Ophthalmol 2006;124:1201-1202.
262.             Lam A, Lee Henry C, Ho AC, Regillo CD, McNamara JA, Fineman MS. Photodyamic therapy in young patients. Ophthal Surg Lasers 2006;37:182-189.
263.             Smith BT, Vander JF, Regillo CD, Ho AC. Evaluation of the potential acuity meter in predicting visual acuity after photodynamic therapy for choroidal neovascularization. Ophthal Surg Lasers 2006;37:6-11.
264.             Chieh JJ, Roth DB, Liu M, Belmont J, Nelson M, Regillo C, Martidis A. Intravitreal triamcinolone for diabetic macular edema. Retina 2005;25:828-834.
265.             Kupperman BD, Thomas EL, de Smet MD, et al (Vitrase for Vitreous Hemorrhage Study Group). Pooled efficacy results from two multinational randomized controlled clinical trials of a single, intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:573-584.
266.             Kupperman BD, Thomas EL, de Smet MD, et al (Vitrase for Vitreous Hemorrhage Study Group). Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:585-597.
267.             Sharma MC, Regillo CD, Shuler MF, Borrillo JL, Benson WE. Determination of the incidence and clinical characteristics of subsequent retinal tears following treatment of the acute posterior vitreous detachment-related initial retinal tears. Am J Ophthalmol 2004;138:280-284.
268.             Gragoudas ES, Adamis AP, Cunningham ET, Jr., et al (VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group). Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
269.             Nelson ML, Tennant TS, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-691.
270.             The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in patients age-related macular degeneration. 12-month clinical outcomes. Ophthalmology 2003;110:2372-2385.
271.             The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Phase II study results Ophthalmology 2003;110:979-986.
272.             The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD). Interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23:14-23.
273.             Connolly BP, Regillo CD, Eagle RC, Jr., Shields CL, Shields JA, Moran H. The histopathologic effects of transpupillary thermotherapy in human eyes. Ophthalmology 2003;110:415-420.
274.             Ng EYJ, Connolly BP, McNamara JA, Regillo CD, Vander JF, Tasman W. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years. Part 1. Visual function and structural outcome. Ophthalmology 2002;109:928-935.
275.             Connolly BP, Ng EYJ, McNamara JA, Regillo CD, Vander JF, Tasman W. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years. Part 2. Refractive outcome. Ophthalmology 2002;109:936-941.
276.             Benson WE, Regillo CD, Vander JF, Tasman W, Brown GC, Ho AC, McNamara JA. Patient-initiated second medical opinions: their necessity and economic cost. Retina 2001;26:633-638.
277.             Fineman MS, Vander J, Regillo CD, Fineman SW, Brown GC. Hypopyon uveitis in immunocompetent patients treated for Mycobacterium avium complex pulmonary infection with rifabutin. Retina 2001;21:31-33.
278.             Aldave AJ, Gertner GS, Davis GH, Regillo CD, Jeffers JB. Bungee cord-associated ocular trauma. Ophthalmology 2001;108:788-792.
279.             McCabe CM, Flynn HW, Shields CL, Shields JA, Regillo CD, McDonald HR, Berrocal MH, Gass JDM, Mieler WF. Juxtapapillary capillary hemangiomas: clinical features and visual acuity outcomes. Ophthalmology 2000;107:2240-2249.
280.             Shah GK, Stein JD, Sharma S, Sivalingham A, Benson WE, Regillo CD, Brown GC, Tasman W. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. Ophthalmology 2000;107:486-489.
281.             Vander JF, Ho AC, McNamara JA, Regillo CD, Brown GC, Benson WE, Tasman W. Diabetes and retinopathy. Ophthalmology 2000;107:2120-2122.
282.             Fineman MS, Regillo CD, Sergott RC, Spaeth G, Vander J. Transient visual loss and decreased ocular blood flow velocities following a scleral buckling procedure. Arch Ophthalmol 1999;117:1647-1648.
283.             Hassan AS, Johnson MW, Schneiderman TE, Regillo CD, Tornambe PE, Poliner LS, Blodi BA, Elner SG. Management of submacular hemorrhages with intravitreal tPA injection and pneumatic displacement. Ophthalmology 1999;106:1900-1907.
284.             Connolly BP, McNamara JA, Regillo CD, Tasman W, Sharma S. Visual outcomes following laser photocoagulation for threshold retinopathy of prematurity. Ophthalmology 1999;106:1739-1741.
285.             Regillo CD, Blade KA, Custis PH, O'Connell SR. Evaluating persistent and recurrent choroidal neovascularization: the role of indocyanine green angiography. Ophthalmology 1998;105:1821-1826.
286.             Connolly BP, McNamara JA, Sharma S, Regillo CD, Tasman W. A comparison of laser photocoagulation with transcleral cryotherapy in the treatment of threshold retinopathy of prematurity. Ophthalmology 1998;105:1628-1631.
287.             Power MH, Regillo CD, Custis PH. Thrombotic thrombocytopenic purpura associated with Purtscher retinopathy. (Photo Essay) Arch Ophthalmol 1997;115:128-129.
288.             Borne MJ, Tasman W, Regillo CD, Malecha M, Sarin L. Outcomes of vitrectomy for retained lens fragments. Ophthalmology 1996;103:971-976.
289.             Regillo CD, Tidwell J. A small incision technique for suturing a posterior chamber intraocular lens. Ophthalmic Surg Lasers 1996;26:473-475.
290.             Sharpe RW, Bethel KJ, Keefe KS, Levine EM, Regillo CD. Choroidal hematopoiesis in an adult. (Case Report) Arch Ophthalmol 1996;114:1421-1422.
291.             Phillips WB, Regillo CD, Maguire JI. Indocyanine green angiography of idiopathic polypoidal choroidal vasculopathy. Ophthalmic Surg Lasers 1996;27:467-470.
292.             Regillo CD, Brown GC, Savino PJ, Byrnes GA, Benson WE, Tasman WS, Sergott RC. Diabetic papillopathy: Patient characteristics and fundus findings. Arch Ophthalmol 1995;113:889-895.
293.             Gedde S, Regillo CD, Vander J. Advanced proliferative retinopathy and iris neovascularization in an intravenous drug abuser. Ophthalmic Surg 1995;26:85-87.
294.             Ho AC, Sergott RC, Regillo CD, Savino PJ, Lieb WE, Flaharty PM, Bosley TM. Color Doppler hemodynamics of giant cell arteritis. Arch Ophthalmol 1994;112:938-945.
295.             Regillo CD, Benson WE, Maguire JI, Annesley WH. Indocyanine green angiography and occult choroidal neovascularization. Ophthalmology 1994;101:280-288.
296.             Regillo CD, Tasman WS, Brown GC. Surgical management of complications associated with X-linked retinoschisis. Arch Ophthalmol 1993;111:1080-1086.
297.             Regillo CD, Sergott RC, Ho AC, Belmont JB, Fischer DH. Hemodynamic alterations in the acute retinal necrosis syndrome. Ophthalmology 1993;100:1171-1176.
298.             Regillo CD, Sergott RC, Brown GC. Successful scleral buckling procedures decrease central retinal artery blood flow velocity. Ophthalmology 1993;100:1044-1049.
299.             Regillo CD, Eagle RC, Shields JA, Shields CL, Arbizo VV. Histopathologic findings in congenital grouped pigmentation of the retina. Ophthalmology 1993;100:400-405.
300.             Regillo CD, Vander JF, Duker JS, Fischer DH, Belmont JB, Kleiner R. Repair of retinitis-related retinal detachments with silicone oil in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1992;113:21-27.
301.             Regillo CD, Shields CL, Shields JA, Eagle RC, Lehr J. Ocular tuberculosis. (Photo Essay) JAMA 1991;266:1490.
302.             Pihan G, Regillo C, Szabo S. Free radicals and lipid peroxidation in ethanol or aspirin-induced gastric mucosal injury. Dig Dis Sci 1987;32:1395-1401.

Awards and Honors

2024 The Ophthalmologist Power List 2024 (Top 100 most influential people in the

world of ophthalmology)

2024 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2023 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2022 The Ophthalmologist Power List 2022 (Top 100 most influential people in the

world of ophthalmology)

2022 Top 150 Ophthalmologists in the US, Newsweek

2022 Master Contributor Award, Journal of Vitreoretinal Diseases

2022 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2021 Presidential Award, American Society of Retina Specialists

2021 Secretariat Award (Second), American Academy of Ophthalmology

2021 Top 150 Ophthalmologists in the US, Newsweek

2021 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2021 NJ Top Docs, (Ophthalmology-Retina)

2021 Distinguished Contributor Award, Journal of Vitreoretinal Diseases

2020 Founders Award. American Society of Retina Specialists

2020 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2020 The Ophthalmologist Power List 2020 (Top 100 most influential people in the

world of ophthalmology)

2019 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2019 NJ Top Docs, (Ophthalmology-Retina)

2019 Speaker of the Day. Hawaiian Eye-RETINA 2019 Annual Meeting

2018 The Ophthalmologist Power List 2018 (Top 100 most influential people in the

world of ophthalmology)

2018 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2018 Wills Eye Hospital Silver Tray Award

2018 NJ Top Docs, (Ophthalmology-Retina)

2017 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2017 Retina Hall of Fame, Charter Inductee

2016 Lifetime Achievement Award, American Academy of Ophthalmology

2016 150 Top Innovators in Medical and Surgical Retina. Ocular Surgery News

2016 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2015 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2015 F1000 Faculty of the Year Award 2014, Faculty of 1000

2014 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2013 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2013 Best Physicians (Ophthalmology-Retina). Philadelphia Life

2013 Honoree, Montgomery County Medical Society, PA

2013 Top Doctors (Ophthalmology-Retina). Mainline Today Magazine

2012 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2012 Top Doctors (Ophthalmology-Retina). Mainline Today Magazine

2012 Top Physicians (Ophthalmology-Retina). South Jersey Magazine

2012 Best Physicians (Ophthalmology-Retina). Philadelphia Life

2011 150 Top Innovators (Retina). Ocular Surgery News

2011 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2011 Top Physicians (Ophthalmology-Retina). South Jersey Magazine

2011 Top Doctors (Ophthalmology-Retina). US News Top Doctors

2011 Speaker of the Day. Hawaiian Eye-RETINA 2011 Annual Meeting

2010 Top Doc’s (Ophthalmology-Retina). Mainline Today Magazine

137.

2010 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2009 “Best Doctors” (Ophthalmology-Retina). South Jersey Magazine

2008 “Best Poster” 2008 Annual Meeting of the American Academy of Ophthalmology

2008 Secretariat Award, American Academy of Ophthalmology

2008 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2007 Senior Honor Award, American Society of Retinal Specialists

2006 Senior Achievement Award, American Academy of Ophthalmology

2006 Top Doc’s (Ophthalmology-Retina). Philadelphia Magazine

2004 Honor Award, American Society of Retinal Specialists

2002 Top Doc’s (Retina). Philadelphia Magazine

1999 Achievement Award, American Academy of Ophthalmology

1998 Navy Commendation Medal-Ophthalmology Dept, Naval Med Ctr San Diego

1995 M. Weiner Annual Award-Outstanding Clinical Teaching in Ophthalmology,

Ophthalmology Dept, Naval Medical Center San Diego

1994 Top Performer-Medical Officer Training School, Maxwell AFB

1993 Heed Ophthalmic Foundation Fellowship 1993-1994

1992 James S. Shipman Award-Best resident research presentation, Wills Eye Hospital

44th Annual Conference, Philadelphia

1984 Valedictorian, College of Pharmacy, Northeastern University

1982,3,4 President’s Awards, Northeastern University

1984 Hodgkinson Memorial Award, Northeastern University

1984 Roche Laboratories Award, College of Pharmacy, Northeastern University

1984 Sears B. Condit Award, Northeastern University

1981,3 Phi Kappa Phi Award and Honor Society, Northeastern University

1981,3 Rho Chi Scholarship Award and Honor Society, Northeastern University

1983 Sousa Memorial Award, Northeastern University

1982 Dean Keagle Scholarship, College of Pharmacy, Northeastern University